Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 21, 2017
CAMBRIDGE, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, ...
Nov 8, 2017
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a company overview at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 8:45 a.m...
Nov 7, 2017
- ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types - - ATLAS also identifies unique tumor-associated antigen response signatures in patients with lung and colorectal cancers - CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a bi...
Nov 2, 2017
- SITC presentation to highlight ATLAS™ ability in neoantigen selection - - IND filing for neoantigen cancer vaccine, GEN-009, expected in Q1 2018 - - Conference call today at 9 am ET - CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer v...
Oct 26, 2017
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, November 2, 2017 at 9:00 a.m. ET to discuss financial results for the third quarter of 2017. Genocea...
Sep 25, 2017
- Superior ATLASTM platform for neoantigen selection (1) - - Exploring strategic alternatives for GEN-003 -- Announces corporate restructuring - CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company discovering and developing novel vaccines and immunotherapies targeting T ce...
Sep 20, 2017
CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens,  today announced that Chip Clark, president and chief executive officer, will present a company overview at the Cantor Fitzgerald Healthcare Conference o...
Aug 9, 2017
- Recently reported positive top-line 12-month Phase 2b data for GEN-003 in genital herpes -- IND filing for neoantigen cancer vaccine, GEN-009, expected in Q4 2017 - CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting...
Jul 28, 2017
- Pre-Conference symposium, posters, and oral presentation will highlight GEN-003 Phase 2b clinical data - CAMBRIDGE, Mass., July 28, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens, announced today upcoming presentations at ...
Jul 24, 2017
- Statistically significant result on expected Phase 3 primary endpoint with Phase 3 dose -- Positive results on multiple secondary clinical endpoints -- Potentially the first new treatment in more than 20 years for the millions infected with genital herpes -- Conference call today at 8 a.m. ET - CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWI...
Jun 26, 2017
CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it has been added to the Russell 3000® and Russell 2000® Indices as part of the annual reconstitution of the Russell U.S. indexes. T...
May 4, 2017
- Data from GEN-003 Phase 2 trial indicate initial course of injections sustains clinical and virologic efficacy for at least 24 months - - End of Phase 2 meeting successfully completed for GEN-003; expect to be Phase 3-ready by end of 2017 - - Neoantigen cancer vaccine candidate GEN-009 IND filing expected by end of 2017 - - Conference call...
Apr 27, 2017
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 4, 2017 at 9:00 a.m. ET to discuss financial results for the first quarter 20...
Apr 11, 2017
CAMBRIDGE, Mass., April 11, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it has been awarded the World Vaccine Congress 2017 Industry Excellence award for best therapeutic vaccine for GEN-003, an immunotherapy to treat ge...
Mar 29, 2017
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, Ap...
Page:
...
Next Last
 
= add release to Briefcase